Cecilia Brown
Articles by Cecilia Brown
Lauren Averett Byers, MD, will be honored with the award during the TAMEST Annual Conference in February.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
A qualitative study of patients with NSCLC is providing insights into their experiences and perceptions.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
The approval is for certain patients with advanced, unresectable, or metastatic NSCLC with an NRG1 gene fusion.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
Detailed data from the trial will be presented at a medical meeting in 2025.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
The last Surgeon General’s report on tobacco-related disparities was released more than two decades ago in 1998.
A project led by a researcher from the Dana-Farber Cancer Center is the first to receive the four-year grant of $2.5 million.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
The updated analysis was presented at the Society for Immunotherapy in Cancer 2024 Annual Meeting.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Officials Provide Update on Datopotamab Deruxtecan Biologics License Application for NSCLC Treatment
A prior BLA has been voluntarily withdrawn and a new BLA has been submitted for US accelerated approval.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.